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Abstract
Background: Lack of access to insulin and poor health outcomes are issues for both low and high income countries.
This has been accompanied by a shift from relatively inexpensive human insulin to its more expensive analogs,
marketed by three to four main global players. Nonetheless, patent-based market exclusivities are beginning to
expire there for the first generation insulin analogs. This paper adds a global dimension to information on the
U.S. patent landscape for insulin by reviewing the patent status of insulins with emphasis on the situation outside
the US and Europe.
Methods: Using the term “insulin”, we searched for patents listed on the United States Food and Drug Administration’s
(USFDA) Orange Book and the Canadian Online Drug Product Database Online Query and its Patent Register. With this
information, we expanded the search globally using the World Intellectual Property Organization (WIPO) PatentScope
database, the European Patent Office’s INPADOC database and various country-specific Patent Offices.
Results: Patent protected insulins marketed in the U.S. and other countries are facing an imminent patent-expiration
“cliff’ yet the three companies that dominate the global insulin market are continuing to file for patents in and outside
the U.S, but very rarely in Africa. Only a few local producers in the so-called "pharmerging" markets (e.g., Brazil, India,
China) are filing for global patent protection on their own insulins. There is moderate, but statistically significant
association between patent filings and diabetes disease burden.
Conclusions: The global market dominance by a few companies of analog over human insulin will likely continue even
though patents on the current portfolio of insulin analogs will expire very soon. Multinationals are continuing to file for
more insulin patents in the bigger markets with large disease burdens and a rapidly emerging middle class. Off-patent
human insulins can effectively manage diabetes. A practical way forward would be find (potential) generic
manufacturers globally and nudge them towards opportunities to diversify their national insulin markets with
acceptable off-patent products for export.
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Background
The disease burden of diabetes has been steadily rising
and improving access to insulin, long considered an "es-
sential medicine" by many countries as well as the
World Health Organization (WHO) [1], has taken on in-
creasing importance [2]. Essential medicines satisfy the
priority health care needs of societies and are considered
as a basis for public procurement or reimbursement deci-
sions, yet fully one third of the world’s population cur-
rently has no guaranteed access to essential medicines [3].
More than 2 billion people in low and middle income
(LMIC) countries face significant barriers in accessing
basic health services. Nevertheless, the challenge of access
to essential medicines is not limited to low and middle in-
come countries [4].
A recent situational review of global insulin access [5]
notes that although insulin was discovered in 1921, the
drug is unattainable to many globally. There is a wide
* Correspondence: wak@bu.edu
1Department of Global Health, Boston University School of Public Health,
Boston, MA 02118, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kaplan and Beall Journal of Pharmaceutical Policy and Practice  (2017) 10:3 
DOI 10.1186/s40545-016-0072-8
range and complexity of factors that contribute to this
unattainability. This review noted that “… little has been
done globally to address the issue of access, despite the
UN’s political commitment to address non-communicable
diseases and ensure universal access to drugs for these dis-
orders.” Lack of access to insulin is a common issue in the
United States [6] and Europe [7]. Insulin sales in the USA
for 2011 totalled US$8.3 billion, a 14.9 % increase com-
pared with 2010 and U.S. government reimbursement
costs for insulin have been steadily rising as well, compli-
cating access to this vital therapeutic to un- and under-
insured populations [8]. Between 1991 and 2014, there
was a near-exponential upward trend in Medicaid pay-
ments on a per-unit basis for a wide variety of insulin
products regardless of formulation, duration of action,
and whether the product was patented [8]. It has been al-
most a century since the first patient was treated with in-
sulin and recombinant human insulin has been off-patent
around the world for a decade and a half [9, 10]. Yet reim-
bursements for newer, patent-protected insulin analogs in-
creased at a faster rate than reimbursements for older
insulins [8], and older porcine- and bovine insulin prod-
ucts are no longer available on the American market. We
note that manufacturing of beef insulin for human use in
the U.S. was discontinued in 1998 as was the manu-
facturing of pork insulin (Iletin II) for human use in
2006. According to the U.S. Food and Drug Adminin-
stration (FDA) discontinuation of animal-sourced in-
sulins was a voluntary withdrawal of these products
made by the manufacturers and not based on any
FDA regulatory action [11].
All this has been accompanied by a shift from human
insulin to its analogs, marketed by three or four main
global players [12]. In 2000, 86.3 % of insulin used in the
UK was human and 10.7 % analog insulins. By 2008,
however, the use of human insulin had fallen to 23.2 %,
with analogs representing 76.1 % of the total [5]. This
trend toward increasing use of insulin analogues is oc-
curring despite a 2011 World Health Organization
(WHO) report which asserted while many comparative
clinical trials “… find a statistically significant difference
between analogue insulins and standard recombinant
human insulin for some blood glucose measurements,
there is no evidence of a clinically significant difference
in most outcomes” [5]. We will not speculate as to
whether this move towards analogue insulin was moti-
vated by better clinical outcomes or by commercial and
marketing interests [13].
This paper adds a global dimension to the previous in-
formation on the U.S. patent ‘landscape’ for insulin [9].
We review the patent status of insulin from a public
health lens with emphasis on the situation outside the
US and Europe. In a recent study of national Essential
Medicines Lists [1], six of 32 countries (19 %) had
selected insulin analogs as essential medicines, all of
which were amongst the upper middle income countries
and predominantly from the region of the Americas (4
out of 6 countries).
We show that while the present suite of marketed in-
sulins has already expired- or will soon expire- globally
(the so-called insulin patent-expiration “cliff ’) the com-
panies that dominate the global market are continuing
to file for insulin patents in and outside the U.S, albeit
rarely in Africa. We further show that only a few manu-
facturers in the "pharmerging" markets (e.g., Brazil,
India, China) are filing for global patent protection on
their own insulins. We then discuss the possible implica-
tions of this intellectual property (IP) global ecosystem
for access to insulin.
Methods
Patents
Using the term “insulin”, we searched the United States
Food and Drug Administration’s (USFDA) Orange Book
[14] (OB). Companies with marketed products in the US
are required by law to list each of their patents protecting
“… the drug or a method of using the drug… with respect
to which a claim of patent infringement could reasonably
be asserted if a person not licensed by the owner of the pa-
tent engaged in the manufacture, use, or sale of the drug
product” [15]. Companies with medicines on the Canadian
market are similarly required to list patents associated
with their marketed products with Health Canada (HC)
[16–18]. As others have focused on the insulin landscape
in the United States [9], we also collected data in Canada
to further diversify our product and patent datasets. We re-
lied on the Orange Book [14] and Canada’s Drug Product
Database Online Query [16] for our list of marketed insulin
products, regardless of patent status. Luo and Kesselheim
[9] consulted the U.S. Patent Office database to locate
other US products that may have not been included in the
Orange Book. Their product list was the same as ours and
our respective Orange Book patent lists were identical. See
Additional file 1 for the list of products (INN and propri-
etary name) included for the present analysis.
We also checked the DrugBank website [19] which
contains a historical log of patents that have been previ-
ously disclosed in the US or Canada in order to capture
important additional patents that may have expired in
the United States, but might not have expired elsewhere.
We then sorted these data by the supplier company
(e.g., Sanofi, Novo Nordisk, Eli Lilly, Pfizer) and then by
the type of insulin (i.e., human or analog). The term “in-
sulin” provided a better retrieval of relevant patents than
“analog” or any combination of these two terms (see
Additional file 2).
Since the Orange Book and Health Canada databases
do not contain, for example, process patents or patents
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for insulins that are not approved for marketing (i.e.,
under development), we undertook a supplemental
search using several free, public patent databases. We
briefly note that the European Patent Office (EPO) and
World Intellectual Property Organization (WIPO) facili-
tate patent procedures and communications on a global
or regional level. These organizations have the most offi-
cial and complete information on applications as well as
adjunct information. There are well over 100 countries
with a patent office [20] who will have their own website
with patent information but not all have the ability to
search for patents online. There are many commercial
and other third party patent databases, not used in this
study, except as otherwise noted.
Our first patent search used the WIPO PatentScope
database [21]. Although there are no globally-applicable
patents, WIPO keeps record of the nearly global patent
application system. We searched WIPO PatentScope for
patent publications containing the word “insulin” on the
cover page, with a filing date more recent than 1 January
1994, and that were submitted by the four insulin sup-
pliers identified during the previous phase of the project,
namely, Eli Lilly, Pfizer, Novo Nordisk, and Sanofi Aven-
tis. We documented all results found in WIPO Patent-
Scope in the same fashion as for the OB and HC.
Further, we consulted the EPO's International Patent
Documentation (INPADOC) database. INPADOC is
publicly available, has bibliographic information from
over 95 countries and provides information about patent
families, i.e. corresponding patent applications, i.e., pa-
tent applications in different countries which claim the
same first filing date and which normally disclose the
same invention. It also provides information concerning
the legal status of patent applications and patents in
those countries which report status changes [22]. We in-
put all of our starting OB/HC and WIPO publication
numbers and retrieved a list of related patent publica-
tions from around the world by pulling the entire INPA-
DOC extended patent families (a group of related
patents internationally) that were connected to our start-
ing patent data from the United States and Canada [23].
We chose INPADOC for retrieving our international
data because it is a free source, which is important for
reproducibility. As mentioned above, “premium” inter-
national patent databases such as Derwent exist [24], as
well as enhanced premium versions of INPADOC, such
as LexisNexis Total Patent, Thomson Innovation, and
Delphion [22]). There were no patents from India in our
results, and so we undertook a supplementary search
with the Indian Patent Office directly for patent applica-
tions and issued patents filed by these companies [25].
We were careful to group the output data by the start-
ing patent publication, as this allowed us to clearly trace
each patent publication to a marketed product by one of
the four suppliers in the North American market or to a
publication found in WIPO PatentScope. INPADOC
returns patent publication threads. A thread starts from
a single patent application filing and may include mul-
tiple legal events or publications that eventually culmin-
ate in a patent grant. Since multiple legal events are
contained in the same file, we report the number of
INPADOC threads, not the number of individual publi-
cations or issued patents within a given thread, unless
otherwise noted. We have taken this approach because
not all threads in INPADOC are complete, especially for
developing countries, nor do they necessarily end with
the granting of a patent. While our data may not provide
the most up-to-date information on the legal status of a
given filing, our data provide a sound global perspective
on where patent rights are being pursued by various in-
sulin manufacturers. We are further able to use this data
to distinguish the type of technology described in differ-
ent patent documents (e.g., insulin itself, method of
manufacturing insulin, method of using insulin).
Manufacturers
A list of putative insulin manufacturers [26] was gener-
ated based from two major sources: first, a literature re-
view of global market research using LexisNexis®
Academic, ProQuest®, various country market reports
(e.g., Frost & Sullivan Market Report Reviews, Business
Monitor International Pharmaceutical & Healthcare In-
dustry Reports) [27, 28] and second, a review of the
websites of various pharmaceutical companies and
Medicine Regulatory Authorities (MRAs). We reviewed
this generated list of putative insulin producing compan-
ies and searched WIPO PatentScope using the company
name and the search term “insulin” found anywhere in
either the front page of the WIPO published patent ap-
plication or in the Abstract of the patent application,
with a filing date more recent than 1 January 1994.
Data storage and analysis
We created a single database for our main analysis, re-
moved duplicates as well as any documents related to
applications filed more than 20 years ago. In order to
maintain focus upon insulin itself, we also set aside filings
describing devices related to insulin administration. The
complete dataset is in Additional file 3. Our findings in
the area of insulin devices have been published elsewhere
[29] and are briefly mentioned in the Discussion.
Beginning with patent filings as of 1995, we analyzed
what percentage of all patent threads filed in that year
remained in force over time. (See Fig. 1). We performed
a simple correlation analysis using the non-parametric
Spearman’s rank order correlation using Excel®. This
statistical test is independent of whether or not the data
is normally distributed. We looked at the association
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between number of patent threads per country and a)
the diabetes disease burden of that country and b) the
gross national income per capita of that country. See
Additional file 4. Estimates of the average number of
persons with diabetes (2007 and 2010) were obtained
from the International Diabetes Federation Atlas [30].
The average gross national income per capita (current
US dollars) was obtained for various countries from the
World Bank for the years 1995–2015 [31].
Results
Global insulin patents
Most patents on insulin products in the world have
already expired by 2015 yet many markets continue to
be dominated by the brand-name versions marketed by
original patent-holders. Figure 1 plots the percentage of
all OB/HC granted patents on insulin remaining in force
in any given year (based on a 20 year-from-filing patent
life (black markers), and shows how relatively quickly
the Eli Lilly, Novo and Pfizer insulin OB/HC patents are
expiring compared to Sanofi. We confirm that after
2016, between about 5–20% of Pfizer, Eli Lilly and Novo
Nordisk patents listed in the OB/HC remain un-expired
and these percentages rapidly dimish, except for those of
Sanofi who appears to have listed OB/HC patents whose
expirations would extend well into 2030 and beyond
(i.e., derived from a patent application filed in 2010).
Figure 1 also shows the percentage of all granted pat-
ents remaining in force on insulin in any given year
(based on a 20 year-from-filing patent life) for the WIPO
PatentScope data (red markers) for products not on OB/
HC. Novo Nordisk has filed their non-OB/HC insulin
patent appliations in a manner similar to Sanofi, such
that Novo’s expirations tend to be spread out over many
years, unlike the Lilly or Pfizer portfolios. This insulin
patent portfolio of Eli Lilly is likely to expire at least a
decade before that of Novo and Sanofi. The presence of
Pfizer in the insulin landscape is mainly for the non-
injectable powdered human insulin inhalation product
Exubera® but it is certainly worth noting that in 2007,
after 11 years of development and barely one full year of
sales, Pfizer stopped its production [32].
Although Fig. 1 may look similar to a Kaplan-Meier
survivorship analysis, it is not. Unlike a real-world sur-
vivorship analysis, there is no censoring of the data be-
cause all the “subjects” (i.e.,. patent threads) have the
same lifespan, as it were. All threads expire at the end of
20 years from filing and all patent expiries are recorded.
The step function is due to the fact that large groups of
patent filings often come to the end of their patent term
at roughly the same time.
The map in Fig. 2 shows the total number of patent
threads found in the INPADOC database for Lilly,
Sanofi, Novo and Pfizer for patent applications filed after
1995. In Africa, there are two regional patent offices, the
Organisation Africaine de la Propriété Intellectuelle
(OAPI) and the African Regional Intellectual Property
Organization (ARIPO). Each is an intergovernmental
organization for cooperation among African states in pa-
tent and other intellectual property matters. Both have
the capacity to grant applications for patents in its mem-
ber states who are parties to its patent protocol. OAPI
and ARIPO refer to patent filings in countries of primar-
ily French- West Africa and English- East Africa, re-
spectively. 1 There are in total, 37 OAPI/ARIPO African
countries but only between 1 and 5 patent thread filings
per country were found (Fig. 2).
There is "no data" for some countries in Africa and
many in the Middle East. This reflects either a lack of





























































































Fig. 1 The percentage of all granted insulin patents remaining in force in a given year for Eli Lilly, Novo Nordisk, Sanofi Aventis and Pfizer
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filing patent applications on the part of Lilly, Novo,
Sanofi and/or Pfizer. Significantly, Africa has a low num-
ber of patent threads with South Africa having the high-
est. Indeed, the largest number of INPADOC patent
thread filings are in the NAFTA countries (Mexico, U.S.,
Canada), the European Union countries (although not
all), Japan and the BRIC countries (Brazil, Russia, India,
China). Considering all the countries with evidence of
INPADOC patent filings, the association between num-
ber of patent threads per country and the number of
persons with diabetes in that country is moderate but
significantly different than zero (Spearman rank correl-
ation coefficient rho = 0.52; p < <0.005; df = 65). The as-
sociation of patent thread per country with wealth per
capita in that country was weaker and not significant
(rho = 0.19; p = 0.12; df = 65).
The major players in the Canadian, US and European
markets have, not surprisingly, filed patent applications
outside these markets and have received issued patents
on technology claimed by their rapidly expiring Orange
Book/Health Canada patents. They will expire at about
the same time as the corresponding US patent portfolios
(Fig. 1, black markers). Where our study detected Or-
ange Book/Health Canada national patent filings, 64.6%
were in high income, 27.7% were upper-middle income,
and the remaining 7.7% were in lower middle income
countries. Most are restricted to North America, Europe,
Australia, India and China.
Global insulin manufacturers
Issued patents in low income settings were rare, even
when we included regional patent regimes such as
ARIPO or OAPI (Fig. 2). Particularly in Africa (Fig. 2),
third parties may be free to exploit the technology
claimed by the existing- and rapidly expiring-OB/HC
patents as well as that for human insulin. Julphar (Gulf
Pharmaceutical Industries, a UAE company), in early
2015 announced that construction of an insulin factory
would start in Ethiopia [33].
Of the 40 putative insulin manufacturers identified in
low- and middle-income countries, as of this writing we
found only four (Biocon, Wockhardt, Tonghua Dongbao,
Zhuhai Laboratories) that had any publicly available pa-
tent applications related to insulin. These four foreign
manufacturers are filing patent applications primarily in
Europe, the United States, Japan, China, India, South
Korea, Israel, Russian Federation, Mexico, Malaysia,
Canada, Australia, Ukraine, New Zealand and Egypt.
Discussion
It has been suggested [5] that because 53 % of United
States patents on insulin were linked to the delivery de-
vices and not the insulin itself [9], intellectual property
is not a barrier for earlier versions of insulin entering
the market. Patentable innovations in insulin delivery
devices are designed to extend the overall patent protec-
tion of medicine/device product combinations. Such in-
novations are incremental but very common [29].
The statement that insulin IP is not a barrier to mar-
ket entry is accurate only for the presently marketed in-
sulins not linked to devices (Fig. 1: black symbols), and
the main insulin producers are continually filing for pat-
ents on analog insulins in their R&D pipelines so their
market exclusivity (assuming that these patent applica-
tions mature into issued patents) are likely to continue
for years to come (Fig. 1: red symbols). In short, analysis
of publicly-available data on global insulin patents and
manufacturers indicates that the vast majority of the
Fig. 2 A map showing the number of insulin patent threads for Eli Lilly, Novo Nordisk, Sanofi Aventis based on patent applications filed after
1995. The different colors represent the number of insulin patent threads
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world’s insulin markets are dominated by brand-name
manufacturers long after the original product and
process patents have expired.
The North American insulin market is dominated by
the small number of companies who are the sole sup-
pliers of one or more of six insulin analogs, which are
available exclusively as brand name products. There is
no US or Canadian human, non-analog insulin. Al-
though third parties are likely free to exploit technology
claimed by expiring OB/HC patents, it is possible that
existing (i.e., non-expired) IP portfolios of Lilly, Novo,
Sanofi and Pfizer in the U.S. and Canada (Fig. 1: red
symbols) would prevent or hinder such exploitation.
Given that the IP for recombinant human insulin, in-
cluding DNA sequences and vectors is long off-patent,
the existing insulin portfolios are unlikely to be sufficient
to block production of human, recombinant insulin.
Patent barriers are not the main reason for a lack of a
generic version of recombinant human insulin in the U.S.
marketplace or indeed, anywhere else in the world.
Moreover, insulin markets have evolved towards con-
taining the newest, most expensive analog products not
only in the US and Europe but in every measured insulin
market in the world. These shifts greatly complicate ac-
cess to medicines for the 2.8 billion people living on less
than $2 a day, and for many living on higher incomes as
well. Stimulating markets for acceptable, yet older prod-
ucts is critical for changing insulin market dynamics;
otherwise, brand name companies will continue to intro-
duce upgraded and patented products, deeming their
older offerings as obsolete and pulling them from the
market. We do not know what fraction of the domestic
production of insulin in areas outside the US and
Canada is based on producing insulin under license for
Novo Nordisk, Lilly, Sanofi and possibly for Pfizer. The
positive relationship between INPADOC patent threads
for these four large multinational companies and diabetes
prevalence (Additional file 3) we infer as manifestation of
the scaling effect of market size.
We observed that only 10 % of the 40 putative insulin
manufacturers identified in low- and middle-income
countries were filing patent applications related to insu-
lin. From this, we infer that they have intentions to mar-
ket their own insulin in these countries and/or are
already marketing their own insulin. For example, there
are many companies making insulins for the Indian mar-
ket and these products include, among others, purified
bovine insulin (Bovine Longact® from USV), recombin-
ant human insulin (Wosulin®: rDNA human monocom-
ponent isophane Insulin from Wockhardt; Insugen®,
human insulin from Biocon) and various insulin analogs
(Lantus®- insulin glargine from Sanofi Aventis;
Novomix-30®, Soluble insulin aspart 30 %, insulin aspart
protamine 70 % from Novo Nordisk; Glaritus®, Insulin
glargine from Wockhardt; Basalog®, insulin glargine from
Biocon;) and combinations (e.g., Mixulin®, Porcine Insu-
lin 30 %, Isophane Insulin 70 % from Cadila) [34–36].
Consider the following thought experiment: Assume
Company X is producing both human analog insulin
and human non-analog insulin in Ethiopia and wants to
export both (i.e., respectively, a Lantus® and Humulin®
equivalent) into the United States, Europe and a low in-
come country (LIC). At the outset, we reiterate that
within a few years patents in all these destinations (U.S.,
Europe and the LIC), if they exist at all, are unlikely to
be a barrier to commercialization of the analog and
there are no IP barriers to production of recombinant
human insulin.
What regulatory options exist to stimulate more com-
petitive insulin markets? First, if imported into the US
or made in the US under contract with Company X,
both insulins will be regulated as a “drug” not as a bio-
logic [37] and the regulatory dossier would be under the
ANDA (“Abbreviated New Drug Application” pathway
of US FDA Section 505(b)2. Indeed, this pathway was
already used in 2006 for approval of a generic recombin-
ant growth hormone product, Omnitrope® by Sandoz
relying in-part on the FDA’s prior approval of Pfizer’s
pioneer rhGH product, Genotropin® [38].
In August 2014, the US FDA granted tentative ap-
proval for Eli Lilly’s Basaglar®, a recombinantly produced
insulin glargine analog for treating diabetes. As a
505(b)(2) product, approval relied in part on clinical
studies carried out for the originator, Sanofi's Lantus®
(insulin glargine). Basaglar® does not have final approval
due to patent litigation involving Sanofi's patents. Time
to tentative approval was rapid, however. It was exactly
ten months [39]. The same product was approved as a
“biosimilar” in 2014 in Europe. In the US and Europe, a
recombinant version of non-analog human insulin would
follow the same respective pathways [40]. Analog insulin
glargine has recently been approved in Mexico [41] ac-
cording to the biocomparable approvals pathway defined
in 2012 (i.e., Galactus®, under license to PiSA Pharma-
ceuticals). A key issue, at least for the United States
FDA, is whether a biosimilar insulin can be freely
substituted at the pharmacy level [42]. The interchange-
ability of different small-molecule generics leads to sub-
stantially reduced drug pricing. When there is no
interchangeability, it is not clear whether or not price
competition will have an impact unless there is coher-
ence with other policy interventions [43].
It is an open question as to whether or not the LICs
could rely on the regulatory authorities in the US, India
or Mexico and allow marketing of a version of glargine
or human insulin. Notwithstanding the relative ease of
US and European approval of Basaglar®, different manu-
facturing processes may result in subtly different insulin
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products. Such differences between versions of all insulins
and their respective reference products could be expected
[43].
Regulatory solutions can only partly address the struc-
tural problems contributing to uncompetitive off-patent
insulin markets, if they do not address the broader prob-
lems of physician and patient preference. One of the big-
gest barriers to widespread access is the fact that doctors
may be influenced by claims that insulin analogs are su-
perior to human insulin when the evidence is equivocal.
According to the WHO, no clear advantage (with lack of
clinically important benefits) of analog insulin over re-
combinant human insulin has been established [44]. To
be sure, if there are clinical complications associated
with human insulin use, patients may indeed not want
to switch from analog products to a human generic. In
markets dominated by analogs, when a patient gets diag-
nosed (and needs insulin), he/she will likely be given the
(multinational) analog insulin. If the patient feels better,
they would want to continue with the same (analog) insu-
lin and not switch to other (human) products/brands.
Switching to another insulin would mean that a patient
will have to regularly visit the doctor for tests/readings,
and the patient would likely prefer to remain stable with
one insulin. Simply put, the multinational companies have
a wide physician network which reinforces their brand
perceptions. In low- and middle-income countries where
human insulin is still the predominant market share [45]
this behavioral situation may well be less onerous yet, irre-
spective of insulin type, we suspect physician acceptance is
a critical access barrier to overcome.
Finally, once approved for market, the buyers of, as
well as the payers for, these generic human insulins will
need to negotiate for price, although in the US this op-
portunity is limited [46]. At present, the major sellers of
insulin are well organized and their buyers are not. As
pointed out recently [5], by contrast with antiretrovirals,
which were paid for by donors such as the Global Fund,
insulin is not purchased by donors, but rather directly
from country budgets. In situations where pooled pro-
curement of essential medicines is ongoing [47, 48] or
proposed [49], its implementation may have a great in-
fluence on procurement prices for insulins of all types.
Pooled procurement, in principle, avoids the costs of
sustaining local production facilities that may not be vi-
able in any case. However, it is difficult to investigate the
extent to which such pooled procurement is effective in
significantly increasing medicine penetration at the na-
tional level. But if the end result is that lower prices are
being offered and more patients have access to medi-
cines, the health system still benefits. One lesson from
the ARV situation is that a possible barrier to pooled
procurement is a lack of regulatory and procurement
capacity at the country level [50].
Another option that has been used is a restricted tender
system (in contrast to open tenders) for purchasing from
well-known pre-qualified suppliers whose products have
been previously authorised and with whom the procure-
ment authority has had satisfactory results. However, a po-
tential concern is that restricted tendering rounds may
increase the likelihood of market concentration if the
same suppliers win contracts, so that competitors let their
product market authorisations expire. This is challenge
for buyers to be mindful of. Some level of competition is
naturally critical for tendering to work effectively, bearing
in mind that quality and the continuity of supply are also
important considerations [51].
Some arrangements allowing for tenders might be set
up in a way that several manufacturers are selected for
supplying the medicine at the same price. If this can be
done so that competition is still suppressing prices, this
might, in principle, prevent excessive concentration and
its negative effects on future prices [52]. Further, the
time period for which tenders are awarded could be
limited to encourage more diversity in the market. Other
criteria besides price can be included in a request for
tender, such as quality of the product, quality of the
delivery system (e.g., insulin vials versus insulin pens)
and security of supply. The tendering system could be
structured to ensure patients and their doctors retain
adequate choice of subsidised treatments.
A limitation of our method is that, in order for our
study to be feasible and replicable, we confined our inter-
national patent search to the only international patent da-
tabases freely available (i.e., the EPO’s INPADOC via
Espacenet, WIPO PatentScope) and India’s national patent
database where many major generic pharmaceutical com-
panies are based. However, there are other premium inter-
national patent databases (e.g., Derwent) and all other
national patent databases [20, 53] which may yield add-
itional records. Nonetheless, the EPO and the WIPO fa-
cilitate procedures and communications on a global or
regional level. These organizations have the most official
and complete information on global applications as well
as adjunct information. They should always be used for
any serious research that has legal and financial ramifica-
tions and for verifying information found in other sources.
Conclusions
This global analysis of patents and producers of global
insulin documents that for most of the world there is lit-
tle to no alternatives to brand-named analog insulins
and non-analog human alternatives in low- and middle-
income countries. The market dominance of analog over
human insulin is not a function of intellectual property
exclusivity as patents on human insulin have expired
long ago. Although patents on the current portfolio of
analogs will expire very soon, there are many patent
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filings and granted patents on insulins that are not mar-
keted in the United States so a very few companies are
enjoying complete monopolies in these markets for a
surprisingly long time. The moderate, but statistically
significant association between patent filings and dia-
betes disease burden suggests these multinationals are
filing for more patents in the bigger markets with large
numbers of persons with diabetes and an rapidly emer-
ging middle class, although these bigger markets (Brazil,
India, China) are not the wealthiest per capita. This
should not be a surprise to anyone.
Mapping the patent estates on insulins is a first step in
encouraging manufactures globally to consider this op-
portunity to enter other, far smaller markets. We need
to identify other bottlenecks in the global insulin market
and to ensure that by 2022, the centenary of the first
person with diabetes to be treated with insulin, all those
requiring this life-saving medicine have access to afford-
able versions of it. More than 80 % of diabetes deaths
occur in low- and middle-income countries [54].
Yet there are also many challenges in trying to produce
copies using current biotechnological approaches without
an appropriate internationally agreed process of regulation.
Off-patent human insulins can effectively manage diabetes.
Others have observed the need for older insulins to be
manufactured [10] and our findings support and under-
score this need. A practical way forward would be to find
(potential) generic manufacturers globally and incentivize
them towards opportunities to diversify their national insu-
lin markets with acceptable off-patent products for export.
Endnotes
1The OAPI countries include: : Benin, Burkina Faso,
Cameroon, Central African Republic, Chad, Comoros,
Congo, Côte d'Ivoire, Gabon, Guinea, Equatorial Guinea,
Mali, Mauritania, Niger, Guinea Bissau, Senegal and Togo.
The ARIPO countries include: Botswana, Gambia, Ghana,
Kenya, Lesotho, Liberia, Malawi, Mozambique, Namibia,
Rwanda, Sào Tomé and Príncipe, Sierra Leone, Somalia,
Sudan, Swaziland,Tanzania,Uganda,Zambia, Zimbabwe
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Additional file 1: Product Table: Patented products in North American
market stratified by company and insulin analogue. (DOCX 15.2 KB)
Additional file 2: Analysis of patent searching using ‘insulin’ and/or
‘analogue/analog”. A. doc file with search results showing that using the
word “analog” or “analogue” as an added search term does not increase
the number of patent search result “hits”. (DOCX 131 KB)
Additional file 3: Complete dataset of issued patents and patent
applications. This file has two tabs: “Post-1995” contains results of all
patent searches in which the initial patent application has a priority date
after 31 December 1994. “Family size comparison” analyses the number
of different patent “threads” for the data in the prior tab. Patent ‘threads”
are described in the text. (XLSX 876 KB)
Additional file 4: Spearman’s Rho coefficient. This file shows the data
used to calculate the non-parametric Spearman’s rank correlation
between the number of patent ‘threads” and the a) average number of
persons with diabetes x 100 (2007–2010); b) the average GNI/capital
(1995–2015). (XLSX 18.6 KB)
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